Filing Flows › Castle Biosciences (CSTL) › Q4 2025
Castle Biosciences (CSTL) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Castle Biosciences (CSTL) reported revenue of $87.0M for the fourth quarter 2025 (Q4 2025), +0.8% from a year earlier and +5% from the quarter before. Operating margin was -4.4%, net loss $2.3M (2.7% of revenue).
Castle Biosciences, Q4 2025: revenue $87.0M (+0.8% year over year), operating margin -4.4%, net loss $2.3M, operating cash flow $26.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $87.0M | +5% | +0.8% |
| Operating profit | −$3.8M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | $26.9M | +19% | +11% |
| Free cash flow | $19.7M | +153% | +18% |
What changed
Revenue was $87.0M in Q4 2025, up 1% year over year and up 5% from the previous quarter. Dermatologic was the largest line at 56% of revenue.
Operating costs exceeded revenue by $3.8M, an operating margin of -4.4%. Total costs grew 10% against revenue growth of 1%. The fastest-growing cost line was Research & development (+15%). The quarter ended with a net loss of $2.3M, wider than the previous quarter's $501K loss. Non-operating items added $1.1M, -41% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $26.9M (up 11% year over year). Non-cash charges added back $3.8M of depreciation and amortization and $11.4M of share-based compensation. Working capital and other items added $14.1M. Capital expenditures of $7.2M left free cash flow of $19.7M.
Questions
What was Castle Biosciences' revenue in the fourth quarter 2025?
Castle Biosciences (CSTL) reported revenue of $87.0M for the fourth quarter 2025 (Q4 2025), +0.8% from a year earlier and +5% from the quarter before.
Was Castle Biosciences profitable in the fourth quarter 2025?
Operating loss was $3.8M (-4.4% of revenue) and net loss $2.3M.
Source: Castle Biosciences 10-K on SEC EDGAR.